BMS 599626 dihydrochloride
目录号 : GC14136
EGFR and ErbB2 inhibitor,potent and selective
Cas No.:1781932-33-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BMS 599626 dihydrochloride is a potent and selective inhibitor of EGFR and ErbB2 with IC50 values of 22 and 32 nM, respectively [1].
The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation. Receptor tyrosine-protein kinase erbB-2 (ErbB2) is a human epidermal growth factor receptor and plays a critical role in breast cancer.
BMS 599626 dihydrochloride is a potent and selective EGFR and ErbB2 inhibitor. BMS-599626 inhibited HER4 with IC50 value of 190 nM. In Sal2, N87 and GEO tumor cells, BMS-599626 inhibited phosphorylation of HER1 and HER2 in a dose-dependent way and inhibited cell proliferation. In AU565 breast cancer cells, BMS-599626 (1μM) inhibited HER1/HER2 heterodimer formation [1]. In tumor cells that forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization [2].
In the L2987 human lung tumors xenograft models, BMS-599626 (60 mg/kg) inhibited and delayed tumor growth in a dose-dependent way [1].
References:
[1]. Gavai AV, Fink BE, Fairfax DJ, et al. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem, 2009, 52(21): 6527-6530.
[2]. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res, 2006, 12(20 Pt 1): 6186-6193.
| Cas No. | 1781932-33-9 | SDF | |
| 化学名 | (E)-(S)-morpholin-3-ylmethyl hydrogen ((Z)-4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)imino)-5-methyl-1,4-dihydropyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonimidate dihydrochloride | ||
| Canonical SMILES | CC(C(/N=C(OC[C@]1([H])COCCN1)\O)=CN2NC=N/3)=C2C3=N\C4=CC=C5C(C=NN5CC6=CC(F)=CC=C6)=C4.Cl.Cl | ||
| 分子式 | C27H27FN8O3.2HCl | 分子量 | 603.48 |
| 溶解度 | Soluble in DMSO > 10 mM | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6571 mL | 8.2853 mL | 16.5706 mL |
| 5 mM | 0.3314 mL | 1.6571 mL | 3.3141 mL |
| 10 mM | 0.1657 mL | 0.8285 mL | 1.6571 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet